Allena Pharmaceuticals Inc (NASDAQ:ALNA) has received an average recommendation of “Hold” from the seven analysts that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $35.25.
ALNA has been the subject of several recent research reports. Wedbush reissued a “buy” rating on shares of Allena Pharmaceuticals in a report on Monday, December 18th. ValuEngine raised Allena Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Zacks Investment Research lowered Allena Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, February 13th. Credit Suisse Group decreased their price objective on Allena Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a report on Wednesday, March 28th. Finally, Roth Capital initiated coverage on Allena Pharmaceuticals in a report on Monday, April 2nd. They issued a “buy” rating and a $61.00 price objective for the company.
ALNA traded up $0.98 during trading hours on Wednesday, hitting $13.65. The stock had a trading volume of 25,204 shares, compared to its average volume of 83,540. Allena Pharmaceuticals has a 1 year low of $6.13 and a 1 year high of $17.56. The firm has a market cap of $262.21 and a P/E ratio of -2.64. The company has a debt-to-equity ratio of 0.07, a quick ratio of 12.74 and a current ratio of 12.74.
Allena Pharmaceuticals (NASDAQ:ALNA) last announced its quarterly earnings data on Tuesday, March 27th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.06. research analysts predict that Allena Pharmaceuticals will post -2.03 earnings per share for the current fiscal year.
A number of hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp purchased a new position in Allena Pharmaceuticals during the 4th quarter valued at about $102,000. Dean Capital Investments Management LLC purchased a new position in Allena Pharmaceuticals during the 4th quarter valued at about $116,000. Deutsche Bank AG purchased a new position in Allena Pharmaceuticals during the 4th quarter valued at about $118,000. Needham Investment Management LLC purchased a new position in Allena Pharmaceuticals during the 4th quarter valued at about $259,000. Finally, Millennium Management LLC purchased a new position in Allena Pharmaceuticals during the 4th quarter valued at about $225,000. 84.13% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Macon Daily and is the property of of Macon Daily. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://macondaily.com/2018/04/16/allena-pharmaceuticals-inc-alna-given-average-rating-of-hold-by-analysts-updated.html.
Allena Pharmaceuticals Company Profile
Allena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones.
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.